Steven Burill, to Give Plenary Keynote at Genome-wide Partnering & Deal-making, May 30-31, Boston
G. Steven Burill, CEO, Burill &Co. will be giving a plenary keynote presentation entitled “Innovating in the New Austerity: What’s Really Happening and Why Creative Dealmaking is Essential” at the Genome-wide Partnering & Deal-making conference (May 30-31, 2012 in Boston, MA)
Alexander Hillisch from Bayer, to Speak at Medicinal Chem. Conf. (June 7-8, 2012, San Diego)
Alexander Hillisch, Director of Medicinal Chemistry & Head of Computational Chemistry at Bayer to give a Featured Presentation on “Ligand and Structure-based ADMET Prediction: Tools and Applications in Lead Finding and Optimization” at the 6th Drug Design & Medicinal Chemistry Conference (June 7-8, 2012 in San Diego, CA)
The Joint Commission to Speak at Diabetes Centers of Excellence Conference
The first diabetes conference focusing on the unique business and administrative challenges of providing disease specific healthcare services has been announced by producer, GTC. The Diabetes Centers of Excellence Conference is scheduled May 15-17, 2012 at the Meliá Atlanta hotel.
The Joint Commission to Speak at Cardiac Centers of Excellence Conference
The Cardiac Centers of Excellence Conference will be held May 15-17, 2011 at the Meliá Atlanta hotel, conference producer GTC has announced. Uniquely focused on the business and administrative challenges of leading a center or hospital cardiac care department, the Conference will include a series of case studies from healthcare executives.
The Joint Commission to Speak at Cancer Centers of Excellence Conference
The Cancer Centers of Excellence Conference will be held May 15-17, 2012 in the Meliá Atlanta hotel, conference producer GTC has confirmed.
The Joint Commission to Speak at Healthcare Centers of Excellence Summit
M. J. Hampel, MPH, MBA, Senior Associate Director, Disease Specific Certification, The Joint Commission will serve as a keynote speaker at the Healthcare Centers of Excellence Summit.
GTC’s Clinical Sequencing Workshop to Be Held at Hyatt Harborside, Boston, on May 29, 2012
Next-generation sequencing is undergoing accelerating translation into the clinical realm and is transforming the research sequencing landscape. Several clinical diagnostic tests are available that employ next-generation sequencing and many companies/laboratories have announced launch dates and development plans for additional tests. Some of these products afford improvements on existing themes by harnessing the capacity of next-generation sequencers to increase clinical sensitivity by analyzing disease loci more comprehensively than previously possible. Other products exploit unique characteristics of next-generation sequencing methods to enable entirely new diagnostic assays. These technologies have enabled a plethora of new discoveries by allowing us to answer questions more cost-effectively than in past and ask questions that were impossible to address by capillary electrophoresis sequencing or high density chip platforms.
Richard Lewis at Amgen to Speak at the 7th Protein Kinases Conference – May 30-31, 2012 in Boston
Richard Lewis, Principal Scientist, Amgen to give a Presentation on “The Discovery & Optimisation of a Novel Class of Potent, Selective and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer” at the 7th Protein Kinases in Drug Discovery Conference (May 30-31, 2012 in Boston, MA)
“Developing a Sustainable Healthcare Business Model” Workshop to Be Held on May 15, 2012 in Atlanta
GTC is proud to announce the Pre-Summit Workshop, “Developing a Sustainable Healthcare Business Model.” The workshop to be held on May 15th, 2012 will directly precede the Healthcare Centers of Excellence Summit at the Meliá Atlanta Hotel in Atlanta, GA.
Hans-Juergen Woerle, VP at Boehringer Ingelheim, to Speak at Diabetes Summit, April 2012 Boston
Hans-Juergen Woerle, MD, Associate Professor, Internal Medicine, Vice President and Head of Therapeutic Area Metabolism at Boehringer Ingelheim, Ingelheim, Germany, will be giving a plenary keynote presentation entitled “Diabetes Drug Development in Light of the New FDA CV Guidance: Experience from the Recent Linagliptin Registration” at the 2nd Diabetes Summit to be held on April 19-20, 2012 in Boston, MA by GTC.